表紙
市場調查報告書
商品編碼
974459

多發性硬化症治療藥的全球市場:產業趨勢與未來預測 (到2027年)

Global Multiple Sclerosis Treatment Market - Industry Trends and Forecast to 2027

出版日期: | 出版商: Data Bridge Market Research Private Limited | 英文 553 Pages | 商品交期: 3-5個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球多發性硬化症治療藥的市場規模,預計2020年∼2027年記錄4.5%的年複合成長率。

本報告提供全球多發性硬化症的治療藥的市場相關分析,市場基本結構和促進、阻礙因素,整體市場規模趨勢預測,疾病/治療方法/藥物的各類型、各給藥途徑、各終端用戶、各流通管道、各地區的詳細趨勢,市場競爭環境,主要企業簡介等調查。

目錄

第1章 簡介

第2章 市場區隔

第3章 摘要整理

第4章 開發平台分析

第5章 全球多發性硬化症治療藥市場:法規趨勢

第6章 市場概要

  • 促進因素
    • 多發性硬化症的盛行率的增加
    • 多發性硬化症治療藥相關大範圍的研究開發 (R&D) 活動
    • 政府的配合措施強化
    • 多發性硬化症的更佳治療藥選擇的需求擴大
  • 阻礙因素
    • 專利到期
    • 治療費高
  • 市場機會
    • 對多發性硬化症治療藥的認識提高
    • 緩解疾病藥的引進
    • 強力的開發平台藥物的存在
  • 課題
    • 多發性硬化症治療藥的副作用增加
    • 多發性硬化症治療藥的限制

第7章 新型冠狀病毒感染疾病 (COVID-19):對醫療產業、多發性硬化症治療藥市場的影響

  • 概要
  • 價格的影響
  • 需求的影響
  • 供應鏈的影響
  • 製造商的策略性決策
  • 結論

第8章 全球多發性硬化症治療藥市場:疾病的各類型

  • 概要
  • RRMS (復髮型多發性硬化症)
  • SPMS (次發性進展型多發性硬化症)
  • PPMS (一次進行性多發性硬化症)
  • RES (重度的復發型多發性硬化症)

第9章 全球多發性硬化症治療藥市場:治療藥的各類型

  • 概要
  • 預防治療
    • 口服藥
    • 注射藥
    • 注射劑
    • 造血幹細胞移植(HSCT)
  • 急性惡化的進行性抑制療法
    • 皮質類固醇
    • 免疫抑制劑
    • 腎上腺皮質刺激荷爾蒙
    • 血漿替換
    • 靜脈內免疫球蛋白
    • 其他
  • 症候性療法

第10章 全球多發性硬化症治療藥市場:藥物的各類型

  • 概要
  • 品牌藥
    • TECFIDERA
    • GILENYA
    • AUBAGIO
    • AVONEX
    • TYSABRI
    • REBIF
    • COPAXONE
    • 8 BETASERON
    • AMPYRA/FAMPYRA
    • 其他
  • 學名藥

第11章 全球多發性硬化症治療藥市場:各給藥途徑

  • 概要
  • 口服給藥
  • 非口服給藥
    • 點滴
    • 皮下注射
    • 其他

第12章 全球多發性硬化症治療藥市場:各終端用戶

  • 概要
  • 醫院
  • 居家護理
  • 專門中心
  • 其他

第13章 全球多發性硬化症治療藥市場:各流通管道

  • 概要
  • 零售
    • 零售藥局
    • 醫院藥局
  • 直接競標

第14章 全球多發性硬化症治療藥市場:各地區

  • 概要
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 新加坡
    • 馬來西亞
    • 泰國
    • 印尼
    • 菲律賓
    • 越南
    • 其他的亞太地區各國
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 西班牙
    • 俄羅斯
    • 瑞士
    • 比利時
    • 土耳其
    • 奧地利
    • 挪威
    • 匈牙利
    • 立陶宛
    • 愛爾蘭
    • 波蘭
    • 其他的歐洲各國
  • 中東、非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 以色列
    • 科威特
    • 埃及
    • 其他的中東、非洲各國
  • 南美
    • 巴西
    • 阿根廷
    • 秘魯
    • 其他的南美各國

第15章 全球多發性硬化症治療藥市場:企業形勢

  • 企業佔有率分析:全球整體
  • 企業佔有率分析:北美
  • 企業佔有率分析:歐洲
  • 企業佔有率分析:亞太地區

第16章 SWOT分析

第17章 企業簡介

  • BIOGEN
  • NOVARTIS AG
  • GENZYME CORPORATION (SANOFI的子公司)
  • MERCK KGAA
  • TEVA PHARMACEUTICALS USA, INC. (TEVA PHARMACEUTICALS INDUSTRIES LTD.的子公司)
  • F. HOFFMANN-LA ROCHE LTD
  • ACORDA THERAPEUTICS, INC.
  • ADAMAS PHARMACEUTICALS, INC.
  • AMNEAL PHARMACEUTICALS LLC
  • BAYER AG
  • CELGENE CORPORATION (BRISTOL-MYERS SQUIBB COMPANY的子公司)
  • HIKMA PHARMACEUTICALS PLC
  • LANNETT
  • MALLINCKRODT
  • MYLAN N.V.
  • PAR PHARMACEUTICAL (ENDO INTERNATIONAL PLC的子公司)
  • PFIZER INC.
  • ZYDUS PHARMACEUTICALS, INC. (ZYDUS CADILA的子公司)

第18章 調查問卷

第19章 相關分析

目錄

Global multiple sclerosis treatment market is projected to register a healthy CAGR of 4.5% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:

Global Multiple Sclerosis Treatment Market, By Disease Type (Relapsing-Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS), Severe Relapsing-Remitting Multiple Sclerosis (RES)), Treatment (Preventive Therapies, Abortive Therapies/Treatment of Acute Exacerbations, Symptomatic Therapies), Drug Type (Branded, Generic), Route of Administration (Oral, Parenteral), End User (Hospital, Homecare, Specialty Centers, Others), Distribution Channel (Retail Sales, Direct Tender), Country (U.S., Canada and Mexico, U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland and rest of Europe, China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines Vietnam and rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Israel, Kuwait, Egypt and rest of Middle East and Africa, Brazil, Argentina, Peru and rest of South America) Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of global multiple sclerosis treatment market:

  • Increasing prevalence of multiple sclerosis
  • Extensive research and development activity in multiple sclerosis treatment

Market Players

The key market players for Global multiple sclerosis treatment market is listed below:

  • Genzyme Corporation (A Subsidiary of Sanofi)
  • Teva Pharmaceuticals USA, Inc. (A Subsidiary of Teva Pharmaceuticals Industries Ltd.)
  • F. Hoffmann-La Roche Ltd, Merck KGaA
  • Mallinckrodt
  • Pfizer Inc.
  • Hikma Pharmaceuticals PLC
  • Par Pharmaceutical (A Subsidiary of Endo International plc),
  • Mylan N.V.
  • Acorda Therapeutics, Inc.
  • Novartis AG
  • Biogen
  • CELGENE CORPORATION (A Subsidiary of Bristol-Myers Squibb Company)
  • Lannett
  • Zydus Pharmaceuticals, Inc. (A Subsidiary of Zydus Cadila)
  • Bayer AG
  • Amneal Pharmaceuticals LLC
  • Adamas Pharmaceuticals, Inc.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET
  • 1.4 CURRENCY AND PRICING
  • 1.5 LIMITATIONS
  • 1.6 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 DISEASE TYPE LIFELINE CURVE
  • 2.8 DBMR MARKET POSITION GRID
  • 2.9 VENDOR SHARE ANALYSIS
  • 2.10 SECONDARY SOURCES
  • 2.11 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PIPELINE ANALYSIS

5 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: REGULATIONS

6 MARKET OVERVIEW

  • 6.1 DRIVERS
    • 6.1.1 INCREASING PREVALENCE OF MULTIPLE SCLEROSIS
    • 6.1.2 EXTENSIVE RESEARCH AND DEVELOPMENT ACTIVITY IN MULTIPLE SCLEROSIS TREATMENT
    • 6.1.3 RISING GOVERNMENT INITIATIVES
    • 6.1.4 INCREASING NEED FOR BETTER MULTIPLE SCLEROSIS TREATMENT OPTIONS
  • 6.2 RESTRAINTS
    • 6.2.1 PATENT EXPIRY OF DRUGS
    • 6.2.2 HIGH COST OF TREATMENT
  • 6.3 OPPORTUNITIES
    • 6.3.1 INCREASING AWARENESS FOR MULTIPLE SCLEROSIS TREATMENT
    • 6.3.2 INTRODUCTION OF DISEASE-MODIFYING DRUGS
    • 6.3.3 PRESENCE OF STRONG PIPELINE DRUGS
  • 6.4 CHALLENGES
    • 6.4.1 INCREASING SIDE EFFECT OF MULTIPLE SCLEROSIS MEDICATION
    • 6.4.2 LIMITATIONS IN MULTIPLE SCLEROSIS THERAPY

7 COVID-19 IMPACT ON GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET IN HEALTHCARE INDUSTRY

  • 7.1 OVERVIEW
  • 7.2 PRICE IMPACT
  • 7.3 IMPACT ON DEMAND
  • 7.4 IMPACT ON SUPPLY CHAIN
  • 7.5 STRATEGIC DECISIONS FOR MANUFACTURERS
  • 7.6 CONCLUSION

8 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE

  • 8.1 OVERVIEW
  • 8.1 RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)
  • 8.2 SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS)
  • 8.3 PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS)
  • 8.4 SEVERE RELAPSING-REMITTING MULTIPLE SCLEROSIS (RES)

9 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT

  • 9.1 OVERVIEW
  • 9.2 PREVENTIVE THERAPIES
    • 9.2.1 ORAL MEDICATION
      • 9.2.1.1 TECFIDERA
      • 9.2.1.2 GILENYA
      • 9.2.1.3 AUBAGIO
      • 9.2.1.4 MAVENCLAD
      • 9.2.1.5 MAYZENT
      • 9.2.1.6 VUMERITY
      • 9.2.1.7 OTHERS
    • 9.2.2 INJECTABLE MEDICATION
      • 9.2.2.1 INTERFERON BETA-1A
        • 9.2.2.1.1 AVONEX
        • 9.2.2.1.2 REBIF
        • 9.2.2.1.3 OTHERS
      • 9.2.2.2 GLATIRAMER ACETATE
        • 9.2.2.2.1 COPAXONE
        • 9.2.2.2.2 GLATOPA
        • 9.2.2.2.3 OTHERS
      • 9.2.2.3 INTERFERON BETA-1B
        • 9.2.2.3.1 BETASERON
        • 9.2.2.3.2 EXTAVIA
      • 9.2.2.4 PLEGRIDY/PEGINTERFERON BETA-1A
      • 9.2.2.5 CHEMOTHERAPY DRUG
      • 9.2.2.6 MONOCLONAL ANTIBODIES
    • 9.2.3 INFUSED MEDICATION
      • 9.2.3.1 TYSABRI
      • 9.2.3.2 OCREVUS
      • 9.2.3.3 LEMTRADA
      • 9.2.3.4 MITOXANTRONE
      • 9.2.3.5 NOVANTRONE
      • 9.2.3.6 OTHERS
    • 9.2.4 HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
  • 9.3 ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS
    • 9.3.1 CORTICOSTEROIDS
      • 9.3.1.1 ORAL PREDNISONE
      • 9.3.1.2 METHYLPREDNISOLONE
      • 9.3.1.3 DEXAMETHASONE
      • 9.3.1.4 PREDNISOLONE
      • 9.3.1.5 BETAMETHASONE
      • 9.3.1.6 OTHERS
    • 9.3.2 IMMUNOSUPPRESSANTS
      • 9.3.2.1 AZATHIOPRINE
      • 9.3.2.2 CYCLOPHOSPHAMIDE
      • 9.3.2.3 METHOTREXATE
      • 9.3.2.4 MITOXANTRONE
      • 9.3.2.5 OTHERS
    • 9.3.3 ADRENOCORTICOTROPIC HORMONE
    • 9.3.4 PLASMAPHERESIS
    • 9.3.5 INTRAVENOUS IMMUNOGLOBULIN
    • 9.3.6 OTHERS
  • 9.4 SYMPTOMATIC THERAPIES
      • 9.4.1.1 MUSCLE RELAXANTS
        • 9.4.1.1.1 LIORESAL
        • 9.4.1.1.2 ZANAFLEX
        • 9.4.1.1.3 OTHERS
      • 9.4.1.2 FATIGUE MEDICATIONS
        • 9.4.1.2.1 GOCOVRI
        • 9.4.1.2.2 OSMOLEX
        • 9.4.1.2.3 PROVIGIL
        • 9.4.1.2.4 RITALIN
        • 9.4.1.2.5 OTHERS
      • 9.4.1.3 PHYSIOTHERAPY
      • 9.4.1.4 LAXATIVES

10 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE

  • 10.1 OVERVIEW
  • 10.2 BRANDED
    • 10.2.1 TECFIDERA
    • 10.2.2 GILENYA
    • 10.2.3 AUBAGIO
    • 10.2.4 AVONEX
    • 10.2.5 TYSABRI
    • 10.2.6 REBIF
    • 10.2.7 COPAXONE
    • 10.2.8 8 BETASERON
    • 10.2.9 AMPYRA/FAMPYRA
    • 10.2.10 OTHERS
  • 10.3 GENERIC

11 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

  • 11.1 OVERVIEW
  • 11.2 ORAL
  • 11.3 PARENTERAL
    • 11.3.1 INTRAVENOUS
    • 11.3.2 SUBCUTANEOUS
    • 11.3.3 OTHERS

12 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER

  • 12.1 OVERVIEW
  • 12.2 HOSPITALS
  • 12.3 HOMECARE
  • 12.4 SPECIALTY CENTERS
  • 12.5 OTHERS

13 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 13.1 OVERVIEW
  • 13.2 RETAIL SALES
    • 13.2.1 RETAIL PHARMACY
    • 13.2.2 HOSPITAL PHARMACY
  • 13.3 DIRECT TENDER

14 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET, BY GEOGRAPHY

  • 14.1 OVERVIEW
  • 14.2 NORTH AMERICA
    • 14.2.1 U.S.
    • 14.2.2 CANADA
    • 14.2.3 MEXICO
  • 14.3 ASIA-PACIFIC
    • 14.3.1 JAPAN
    • 14.3.2 CHINA
    • 14.3.3 INDIA
    • 14.3.4 SOUTH KOREA
    • 14.3.5 AUSTRALIA
    • 14.3.6 SINGAPORE
    • 14.3.7 MALAYSIA
    • 14.3.8 THAILAND
    • 14.3.9 INDONESIA
    • 14.3.10 PHILIPPINES
    • 14.3.11 VIETNAM
    • 14.3.12 REST OF ASIA-PACIFIC
  • 14.4 EUROPE
    • 14.4.1 GERMANY
    • 14.4.2 FRANCE
    • 14.4.3 U.K.
    • 14.4.4 ITALY
    • 14.4.5 NETHERLANDS
    • 14.4.6 SPAIN
    • 14.4.7 RUSSIA
    • 14.4.8 SWITZERLAND
    • 14.4.9 BELGIUM
    • 14.4.10 TURKEY
    • 14.4.11 AUSTRIA
    • 14.4.12 NORWAY
    • 14.4.13 HUNGARY
    • 14.4.14 LITHUANIA
    • 14.4.15 IRELAND
    • 14.4.16 POLAND
    • 14.4.17 REST OF EUROPE
  • 14.5 MIDDLE EAST & AFRICA
    • 14.5.1 SAUDI ARABIA
    • 14.5.2 SOUTH AFRICA
    • 14.5.3 UAE
    • 14.5.4 ISRAEL
    • 14.5.5 KUWAIT
    • 14.5.6 EGYPT
    • 14.5.7 REST OF MIDDLE EAST & AFRICA
  • 14.6 SOUTH AMERICA
    • 14.6.1 BRAZIL
    • 14.6.2 ARGENTINA
    • 14.6.3 PERU
    • 14.6.4 REST OF SOUTH AMERICA

15 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET, COMPANY LANDSCAPE

  • 15.1 COMPANY SHARE ANALYSIS: GLOBAL
  • 15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
  • 15.3 COMPANY SHARE ANALYSIS: EUROPE
  • 15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

16 SWOT

17 COMPANY PROFILES

  • 17.1 BIOGEN
    • 17.1.1 COMPANY SNAPSHOT
    • 17.1.2 REVENUE ANALYSIS
    • 17.1.3 COMPANY SHARE ANALYSIS
    • 17.1.4 PRODUCT PORTFOLIO
    • 17.1.5 RECENT DEVELOPMENT
  • 17.2 NOVARTIS AG
    • 17.2.1 COMPANY SNAPSHOT
    • 17.2.2 REVENUE ANALYSIS
    • 17.2.3 COMPANY SHARE ANALYSIS
    • 17.2.4 PRODUCT PORTFOLIO
    • 17.2.5 RECENT DEVELOPMENTS
  • 17.3 GENZYME CORPORATION (A SUBSIDIARY OF SANOFI)
    • 17.3.1 COMPANY SNAPSHOT
    • 17.3.2 REVENUE ANALYSIS
    • 17.3.3 COMPANY SHARE ANALYSIS
    • 17.3.4 PRODUCT PORTFOLIO
    • 17.3.5 RECENT DEVELOPMENTS
  • 17.4 MERCK KGAA
    • 17.4.1 COMPANY SNAPSHOT
    • 17.4.2 REVENUE ANALYSIS
    • 17.4.3 COMPANY SHARE ANALYSIS
    • 17.4.4 PRODUCT PORTFOLIO
    • 17.4.5 RECENT DEVELOPMENTS
  • 17.5 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICALS INDUSTRIES LTD.)
    • 17.5.1 COMPANY SNAPSHOT
    • 17.5.2 REVENUE ANALYSIS
    • 17.5.3 COMPANY SHARE ANALYSIS
    • 17.5.4 PRODUCT PORTFOLIO
    • 17.5.5 RECENT DEVELOPMENTS
  • 17.6 F. HOFFMANN-LA ROCHE LTD
    • 17.6.1 COMPANY SNAPSHOT
    • 17.6.2 REVENUE ANALYSIS
    • 17.6.3 PRODUCT PORTFOLIO
    • 17.6.4 RECENT DEVELOPMENTS
  • 17.7 ACORDA THERAPEUTICS, INC.
    • 17.7.1 COMPANY SNAPSHOT
    • 17.7.2 REVENUE ANALYSIS
    • 17.7.3 PRODUCT PORTFOLIO
    • 17.7.4 1.7.4 RECENT DEVELOPMENT
  • 17.8 ADAMAS PHARMACEUTICALS, INC.
    • 17.8.1 COMPANY SNAPSHOT
    • 17.8.2 REVENUE ANALYSIS
    • 17.8.3 PRODUCT PORTFOLIO
    • 17.8.4 RECENT DEVELOPMENT
  • 17.9 AMNEAL PHARMACEUTICALS LLC
    • 17.9.1 COMPANY SNAPSHOT
    • 17.9.2 REVENUE ANALYSIS
    • 17.9.3 PRODUCT PORTFOLIO
    • 17.9.4 RECENT DEVELOPMENT
  • 17.10 BAYER AG
    • 17.10.1 COMPANY SNAPSHOT
    • 17.10.2 1.10.2REVENUE ANALYSIS
    • 17.10.3 PRODUCT PORTFOLIO
    • 17.10.4 RECENT DEVELOPMENT
  • 17.11 CELGENE CORPORATION (A SUBSIDIARY OF BRISTOL-MYERS SQUIBB COMPANY)
    • 17.11.1 COMPANY SNAPSHOT
    • 17.11.2 REVENUE ANALYSIS
    • 17.11.3 PRODUCT PORTFOLIO
    • 17.11.4 RECENT DEVELOPMENTS
  • 17.12 HIKMA PHARMACEUTICALS PLC
    • 17.12.1 COMPANY SNAPSHOT
    • 17.12.2 REVENUE ANALYSIS
    • 17.12.3 PRODUCT PORTFOLIO
    • 17.12.4 RECENT DEVELOPMENTS
  • 17.13 LANNETT
    • 17.13.1 COMPANY SNAPSHOT
    • 17.13.2 REVENUE ANALYSIS
    • 17.13.3 PRODUCT PORTFOLIO
    • 17.13.4 RECENT DEVELOPMENT
  • 17.14 MALLINCKRODT
    • 17.14.1 COMPANY SNAPSHOT
    • 17.14.2 REVENUE ANALYSIS
    • 17.14.3 PRODUCT PORTFOLIO
    • 17.14.4 RECENT DEVELOPMENTS
  • 17.15 MYLAN N.V.
    • 17.15.1 COMPANY SNAPSHOT
    • 17.15.2 REVENUE ANALYSIS
    • 17.15.3 PRODUCT PORTFOLIO
    • 17.15.4 RECENT DEVELOPMENTS
  • 17.16 PAR PHARMACEUTICAL (A SUBSIDIARY OF ENDO INTERNATIONAL PLC)
    • 17.16.1 COMPANY SNAPSHOT
    • 17.16.2 REVENUE ANALYSIS
    • 17.16.3 PRODUCT PORTFOLIO
    • 17.16.4 RECENT DEVELOPMENTS
  • 17.17 PFIZER INC.
    • 17.17.1 COMPANY SNAPSHOT
    • 17.17.2 REVENUE ANALYSIS
    • 17.17.3 PRODUCT PORTFOLIO
    • 17.17.4 RECENT DEVELOPMENTS
  • 17.18 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)
    • 17.18.1 COMPANY SNAPSHOT
    • 17.18.2 REVENUE ANALYSIS
    • 17.18.3 PRODUCT PORTFOLIO
    • 17.18.4 RECENT DEVELOPMENT

18 QUESTIONNAIRE

19 RELATED REPORTS

LIST OF TABLES

  • TABLE 1 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET, PIPELINE ANALYSIS
  • TABLE 2 MULTIPLE SCLEROSIS DRUGS IN PIPELINE
  • TABLE 3 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 1 GLOBAL RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 2 GLOBAL SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 3 GLOBAL PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 4 GLOBAL SEVERE RELAPSING-REMITTING MULTIPLE SCLEROSIS (RES) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 5 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 6 GLOBAL PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 7 GLOBAL PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 8 GLOBAL ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 9 GLOBAL INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 10 GLOBAL INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 11 GLOBAL GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 12 GLOBAL INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 13 GLOBAL INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 14 GLOBAL ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 15 GLOBAL ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 16 GLOBAL CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 17 GLOBAL IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 18 GLOBAL SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 19 GLOBAL SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 20 GLOBAL MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 21 GLOBAL FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 22 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 23 GLOBAL BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 24 GLOBAL BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
  • TABLE 25 GLOBAL GENERIC IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 26 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 27 GLOBAL ORAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 28 GLOBAL PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 29 GLOBAL PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY RUOTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 30 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 31 GLOBAL HOSPITAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 32 GLOBAL HOMECARE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 33 GLOBAL SPECIALTY CENTERS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 34 GLOBAL OTHERS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 35 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 36 GLOBAL RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 37 GLOBAL RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 38 GLOBAL DIRECT TENDER IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 39 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 40 NORTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
  • TABLE 41 NORTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 42 NORTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 43 NORTH AMERICA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 44 NORTH AMERICA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 45 NORTH AMERICA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 46 NORTH AMERICA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 47 NORTH AMERICA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 48 NORTH AMERICA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 49 NORTH AMERICA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 50 NORTH AMERICA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 51 NORTH AMERICA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 52 NORTH AMERICA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 53 NORTH AMERICA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 54 NORTH AMERICA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 55 NORTH AMERICA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 56 NORTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 57 NORTH AMERICA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
  • TABLE 58 NORTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 59 NORTH AMERICA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 60 NORTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 61 NORTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 62 NORTH AMERICA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 63 U.S.MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 64 U.S.MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 65 U.S.PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 66 U.S.ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 67 U.S.INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 68 U.S.INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 69 U.S.GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 70 U.S.INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 71 U.S.INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 72 U.S.ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 73 U.S.CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 74 U.S.IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 75 U.S.SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 76 U.S.MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 77 U.S.FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 78 U.S.MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 79 U.S.BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
  • TABLE 80 U.S.MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 81 U.S.PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 82 U.S.MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 83 U.S.MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 84 U.S.RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 85 CANADA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 86 CANADA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 87 CANADA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 88 CANADA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 89 CANADA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 90 CANADA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 91 CANADA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 92 CANADA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 93 CANADA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 94 CANADA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 95 CANADA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 96 CANADA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 97 CANADA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 98 CANADA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 99 CANADA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 100 CANADA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 101 CANADA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
  • TABLE 102 CANADA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 103 CANADA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 104 CANADA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 105 CANADA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 106 CANADA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 107 MEXICO MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 108 MEXICO MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 109 MEXICO PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 110 MEXICO ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 111 MEXICO INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 112 MEXICO INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 113 MEXICO GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 114 MEXICO INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 115 MEXICO INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 116 MEXICO ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 117 MEXICO CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 118 MEXICO IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 119 MEXICO SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 120 MEXICO MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 121 MEXICO FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 122 MEXICO MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 123 MEXICO BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
  • TABLE 124 MEXICO MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 125 MEXICO PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 126 MEXICO MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 127 MEXICO MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 128 MEXICO RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 129 ASIA-PACIFIC MULTIPLE SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
  • TABLE 130 ASIA-PACIFIC MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 131 ASIA-PACIFICMULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 132 ASIA-PACIFICPREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 133 ASIA-PACIFICORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 134 ASIA-PACIFICINJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 135 ASIA-PACIFICINTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 136 ASIA-PACIFICGLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 137 ASIA-PACIFICINTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 138 ASIA-PACIFICINFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 139 ASIA-PACIFICABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 140 ASIA-PACIFICCORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 141 ASIA-PACIFICIMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 142 ASIA-PACIFICSYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 143 ASIA-PACIFICMUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 144 ASIA-PACIFICFATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 145 ASIA-PACIFIC MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 146 ASIA-PACIFIC BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
  • TABLE 147 ASIA-PACIFIC MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 148 ASIA-PACIFIC PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 149 ASIA-PACIFICMULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 150 ASIA-PACIFICMULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 151 ASIA-PACIFIC RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 152 JAPAN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 153 JAPAN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 154 JAPAN PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 155 JAPAN ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 156 JAPAN INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 157 JAPAN INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 158 JAPAN GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 159 JAPAN INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 160 JAPAN INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 161 JAPAN ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 162 JAPAN CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 163 JAPAN IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 164 JAPAN SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 165 JAPAN MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 166 JAPAN FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 167 JAPAN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 168 JAPAN BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
  • TABLE 169 JAPAN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 170 JAPAN PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 171 JAPAN MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 172 JAPAN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 173 JAPAN RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 174 CHINA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 175 CHINA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 176 CHINA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 177 CHINA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 178 CHINA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 179 CHINA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 180 CHINA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 181 CHINA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 182 CHINA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 183 CHINA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 184 CHINA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 185 CHINA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 186 CHINA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 187 CHINA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 188 CHINA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 189 CHINA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 190 CHINA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
  • TABLE 191 CHINA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 192 CHINA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 193 CHINA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 194 CHINA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 195 CHINA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 196 INDIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 197 INDIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 198 INDIA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 199 INDIA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 200 INDIA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 201 INDIA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 202 INDIA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 203 INDIA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 204 INDIA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 205 INDIA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 206 INDIA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 207 INDIA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 208 INDIA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 209 INDIA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 210 INDIA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 211 INDIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 212 INDIA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
  • TABLE 213 INDIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 214 INDIA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 215 INDIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 216 INDIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 217 INDIA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 218 SOUTH KOREA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 219 SOUTH KOREA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 220 SOUTH KOREA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 221 SOUTH KOREA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 222 SOUTH KOREA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 223 SOUTH KOREA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 224 SOUTH KOREA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 225 SOUTH KOREA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 226 SOUTH KOREA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 227 SOUTH KOREA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 228 SOUTH KOREA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 229 SOUTH KOREA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 230 SOUTH KOREA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 231 SOUTH KOREA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 232 SOUTH KOREA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 233 SOUTH KOREA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 234 SOUTH KOREA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
  • TABLE 235 SOUTH KOREA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 236 SOUTH KOREA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 237 SOUTH KOREA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 238 SOUTH KOREA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 239 SOUTH KOREA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 240 AUSTRALIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 241 AUSTRALIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 242 AUSTRALIA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 243 AUSTRALIA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 244 AUSTRALIA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 245 AUSTRALIA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 246 AUSTRALIA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 247 AUSTRALIA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 248 AUSTRALIA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 249 AUSTRALIA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 250 AUSTRALIA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 251 AUSTRALIA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 252 AUSTRALIA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 253 AUSTRALIA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 254 AUSTRALIA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 255 AUSTRALIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 256 AUSTRALIA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
  • TABLE 257 AUSTRALIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 258 AUSTRALIA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 259 AUSTRALIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 260 AUSTRALIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 261 AUSTRALIA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 262 SINGAPORE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 263 SINGAPORE MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 264 SINGAPORE PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 265 SINGAPORE ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 266 SINGAPORE INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 267 SINGAPORE INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 268 SINGAPORE GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 269 SINGAPORE INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 270 SINGAPORE INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 271 SINGAPORE ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 272 SINGAPORE CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 273 SINGAPORE IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 274 SINGAPORE SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 275 SINGAPORE MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 276 SINGAPORE FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 277 SINGAPORE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 278 SINGAPORE BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
  • TABLE 279 SINGAPORE MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 280 SINGAPORE PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 281 SINGAPORE MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 282 SINGAPORE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 283 SINGAPORE RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 284 MALAYSIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 285 MALAYSIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 286 MALAYSIA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 287 MALAYSIA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 288 MALAYSIA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 289 MALAYSIA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 290 MALAYSIA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 291 MALAYSIA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 292 MALAYSIA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 293 MALAYSIA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 294 MALAYSIA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 295 MALAYSIA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 296 MALAYSIA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 297 MALAYSIA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 298 MALAYSIA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 299 MALAYSIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 300 MALAYSIA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)
  • TABLE 301 MALAYSIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 302 MALAYSIA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 303 MALAYSIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 304 MALAYSIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 305 MALAYSIA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 306 THAILAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 307 THAILAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 308 THAILAND PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 309 THAILAND ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 310 THAILAND INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 311 THAILAND INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 312 THAILAND GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 313 THAILAND INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 314 THAILAND INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 315 THAILAND ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 316 THAILAND CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 317 THAILAND IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 318 THAILAND SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 319 THAILAND MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 320 THAILAND FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 321 THAILAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 322 THAILAND BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)
  • TABLE 323 THAILAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 324 THAILAND PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 325 THAILAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 326 THAILAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 327 THAILAND RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 328 INDONESIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 329 INDONESIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 330 INDONESIA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 331 INDONESIA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 332 INDONESIA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 333 INDONESIA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 334 INDONESIA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 335 INDONESIA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 336 INDONESIA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 337 INDONESIA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 338 INDONESIA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 339 INDONESIA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 340 INDONESIA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 341 INDONESIA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 342 INDONESIA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 343 INDONESIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 344 INDONESIA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)
  • TABLE 345 INDONESIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 346 INDONESIA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 347 INDONESIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 348 INDONESIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 349 INDONESIA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 350 PHILIPPINES MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 351 PHILIPPINES MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 352 PHILIPPINES PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 353 PHILIPPINES ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 354 PHILIPPINES INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 355 PHILIPPINES INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 356 PHILIPPINES GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 357 PHILIPPINES INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 358 PHILIPPINES INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 359 PHILIPPINES ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 360 PHILIPPINES CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 361 PHILIPPINES IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 362 PHILIPPINES SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 363 PHILIPPINES MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 364 PHILIPPINES FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 365 PHILIPPINES MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 366 PHILIPPINES BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)
  • TABLE 367 PHILIPPINES MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 368 PHILIPPINES PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 369 PHILIPPINES MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 370 PHILIPPINES MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 371 PHILIPPINES RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 372 VIETNAM MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 373 VIETNAM MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 374 VIETNAM PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 375 VIETNAM ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 376 VIETNAM INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 377 VIETNAM INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 378 VIETNAM GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 379 VIETNAM INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 380 VIETNAM INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 381 VIETNAM ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 382 VIETNAM CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 383 VIETNAM IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 384 VIETNAM SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 385 VIETNAM MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 386 VIETNAM FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 387 VIETNAM MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 388 VIETNAM BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)
  • TABLE 389 VIETNAM MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 390 VIETNAM PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 391 VIETNAM MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 392 VIETNAM MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 393 VIETNAM RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 394 REST OF ASIA-PACIFIC MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 395 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
  • TABLE 396 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 397 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 398 EUROPE PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 399 EUROPE ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 400 EUROPE INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 401 EUROPE INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 402 EUROPE GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 403 EUROPE INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 404 EUROPE INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 405 EUROPE ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 406 EUROPE CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 407 EUROPE IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 408 EUROPE SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 409 EUROPE MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 410 EUROPE FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 411 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 412 EUROPE BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)
  • TABLE 413 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 414 EUROPE PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 415 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 416 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 417 EUROPE RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 418 GERMANY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 419 GERMANY MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 420 GERMANY PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 421 GERMANY ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 422 GERMANY INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 423 GERMANY INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 424 GERMANY GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 425 GERMANY INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 426 GERMANY INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 427 GERMANY ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 428 GERMANY CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 429 GERMANY IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 430 GERMANY SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 431 GERMANY MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 432 GERMANY FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 433 GERMANY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 434 GERMANY BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)
  • TABLE 435 GERMANY MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 436 GERMANY PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 437 GERMANY MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 438 GERMANY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 439 GERMANY RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 440 FRANCE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 441 FRANCE MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 442 FRANCE PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 443 FRANCE ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 444 FRANCE INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 445 FRANCE INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 446 FRANCE GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 447 FRANCE INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 448 FRANCE INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 449 FRANCE ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 450 FRANCE CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 451 FRANCE IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 452 FRANCE SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 453 FRANCE MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 454 FRANCE FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 455 FRANCE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 456 FRANCE BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)
  • TABLE 457 FRANCE MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 458 FRANCE PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 459 FRANCE MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 460 FRANCE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 461 FRANCE RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 462 U.K. MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 463 U.K. MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 464 U.K. PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 465 U.K. ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 466 U.K. INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 467 U.K. INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 468 U.K. GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 469 U.K. INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 470 U.K. INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 471 U.K. ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 472 U.K. CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 473 U.K. IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 474 U.K. SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 475 U.K. MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 476 U.K. FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 477 U.K. MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 478 U.K. BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)
  • TABLE 479 U.K. MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 480 U.K. PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 481 U.K. MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 482 U.K. MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 483 U.K. RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 484 ITALY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 485 ITALY MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 486 ITALY PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 487 ITALY ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 488 ITALY INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 489 ITALY INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 490 ITALY GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 491 ITALY INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 492 ITALY INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 493 ITALY ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 494 ITALY CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 495 ITALY IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 496 ITALY SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 497 ITALY MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 498 ITALY FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 499 ITALY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 500 ITALY BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)
  • TABLE 501 ITALY MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 502 ITALY PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 503 ITALY MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 504 ITALY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 505 ITALY RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 506 NETHERLANDS MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 507 NETHERLANDS MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 508 NETHERLANDS PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 509 NETHERLANDS ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 510 NETHERLANDS INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 511 NETHERLANDS INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 512 NETHERLANDS GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 513 NETHERLANDS INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 514 NETHERLANDS INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 515 NETHERLANDS ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 516 NETHERLANDS CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 517 NETHERLANDS IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 518 NETHERLANDS SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 519 NETHERLANDS MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 520 NETHERLANDS FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 521 NETHERLANDS MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 522 NETHERLANDS BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)
  • TABLE 523 NETHERLANDS MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 524 NETHERLANDS PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 525 NETHERLANDS MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 526 NETHERLANDS MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 527 NETHERLANDS RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 528 SPAIN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 529 SPAIN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 530 SPAIN PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 531 SPAIN ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 532 SPAIN INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 533 SPAIN INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 534 SPAIN GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 535 SPAIN INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 536 SPAIN INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 537 SPAIN ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 538 SPAIN CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 539 SPAIN IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 540 SPAIN SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 541 SPAIN MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 542 SPAIN FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 543 SPAIN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 544 SPAIN BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)
  • TABLE 545 SPAIN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 546 SPAIN PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 547 SPAIN MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 548 SPAIN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 549 SPAIN RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 550 RUSSIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 551 RUSSIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 552 RUSSIA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 553 RUSSIA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 554 RUSSIA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 555 RUSSIA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 556 RUSSIA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 557 RUSSIA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 558 RUSSIA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 559 RUSSIA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 560 RUSSIA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 561 RUSSIA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 562 RUSSIA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 563 RUSSIA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 564 RUSSIA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 565 RUSSIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 566 RUSSIA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)
  • TABLE 567 RUSSIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 568 RUSSIA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 569 RUSSIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 570 RUSSIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 571 RUSSIA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 572 SWITZERLAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 573 SWITZERLAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 574 SWITZERLAND PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 575 SWITZERLAND ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 576 SWITZERLAND INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 577 SWITZERLAND INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 578 SWITZERLAND GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 579 SWITZERLAND INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 580 SWITZERLAND INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 581 SWITZERLAND ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 582 SWITZERLAND CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 583 SWITZERLAND IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 584 SWITZERLAND SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 585 SWITZERLAND MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 586 SWITZERLAND FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 587 SWITZERLAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 588 SWITZERLAND BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)
  • TABLE 589 SWITZERLAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 590 SWITZERLAND PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 591 SWITZERLAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 592 SWITZERLAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 593 SWITZERLAND RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 594 BELGIUM MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 595 BELGIUM MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 596 BELGIUM PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 597 BELGIUM ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 598 BELGIUM INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 599 BELGIUM INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 600 BELGIUM GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 601 BELGIUM INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 602 BELGIUM INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 603 BELGIUM ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 604 BELGIUM CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 605 BELGIUM IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 606 BELGIUM SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 607 BELGIUM MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 608 BELGIUM FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 609 BELGIUM MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 610 BELGIUM BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)
  • TABLE 611 BELGIUM MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 612 BELGIUM PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 613 BELGIUM MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 614 BELGIUM MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 615 BELGIUM RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 616 TURKEY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 617 TURKEY MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 618 TURKEY PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 619 TURKEY ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 620 TURKEY INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 621 TURKEY INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 622 TURKEY GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 623 TURKEY INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 624 TURKEY INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 625 TURKEY ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 626 TURKEY CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 627 TURKEY IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 628 TURKEY SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 629 TURKEY MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 630 TURKEY FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 631 TURKEY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 632 TURKEY BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)
  • TABLE 633 TURKEY MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 634 TURKEY PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 635 TURKEY MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 636 TURKEY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 637 TURKEY RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 638 AUSTRIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 639 AUSTRIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 640 AUSTRIA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 641 AUSTRIA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 642 AUSTRIA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 643 AUSTRIA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 644 AUSTRIA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 645 AUSTRIA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 646 AUSTRIA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 647 AUSTRIA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 648 AUSTRIA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 649 AUSTRIA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 650 AUSTRIA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 651 AUSTRIA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 652 AUSTRIA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 653 AUSTRIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 654 AUSTRIA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)
  • TABLE 655 AUSTRIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 656 AUSTRIA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 657 AUSTRIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 658 AUSTRIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 659 AUSTRIA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 660 NORWAY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 661 NORWAY MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 662 NORWAY PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 663 NORWAY ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 664 NORWAY INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 665 NORWAY INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 666 NORWAY GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 667 NORWAY INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 668 NORWAY INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 669 NORWAY ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 670 NORWAY CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 671 NORWAY IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 672 NORWAY SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 673 NORWAY MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 674 NORWAY FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 675 NORWAY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 676 NORWAY BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)
  • TABLE 677 NORWAY MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 678 NORWAY PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 679 NORWAY MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 680 NORWAY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 681 NORWAY RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 682 HUNGARY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 683 HUNGARY MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 684 HUNGARY PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 685 HUNGARY ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 686 HUNGARY INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 687 HUNGARY INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 688 HUNGARY GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 689 HUNGARY INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 690 HUNGARY INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 691 HUNGARY ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 692 HUNGARY CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 693 HUNGARY IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 694 HUNGARY SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 695 HUNGARY MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 696 HUNGARY FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 697 HUNGARY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 698 HUNGARY BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)
  • TABLE 699 HUNGARY MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 700 HUNGARY PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 701 HUNGARY MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 702 HUNGARY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 703 HUNGARY RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 704 LITHUANIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 705 LITHUANIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 706 LITHUANIA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 707 LITHUANIA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 708 LITHUANIA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 709 LITHUANIA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 710 LITHUANIA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 711 LITHUANIA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 712 LITHUANIA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 713 LITHUANIA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 714 LITHUANIA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 715 LITHUANIA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 716 LITHUANIA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 717 LITHUANIA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 718 LITHUANIA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 719 LITHUANIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 720 LITHUANIA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)
  • TABLE 721 LITHUANIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 722 LITHUANIA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 723 LITHUANIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 724 LITHUANIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 725 LITHUANIA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 726 IRELAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 727 IRELAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 728 IRELAND PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 729 IRELAND ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 730 IRELAND INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 731 IRELAND INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 732 IRELAND GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 733 IRELAND INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 734 IRELAND INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 735 IRELAND ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 736 IRELAND CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 737 IRELAND IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 738 IRELAND SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 739 IRELAND MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 740 IRELAND FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 741 IRELAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 742 IRELAND BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)
  • TABLE 743 IRELAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 744 IRELAND PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 745 IRELAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 746 IRELAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 747 IRELAND RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 748 POLAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 749 POLAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 750 POLAND PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 751 POLAND ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 752 POLAND INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 753 POLAND INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 754 POLAND GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 755 POLAND INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 756 POLAND INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 757 POLAND ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 758 POLAND CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 759 POLAND IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 760 POLAND SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 761 POLAND MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 762 POLAND FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 763 POLAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 764 POLAND BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)
  • TABLE 765 POLAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 766 POLAND PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 767 POLAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 768 POLAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 769 POLAND RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 770 REST OF EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 771 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
  • TABLE 772 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 773 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 774 MIDDLE EAST & AFRICA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 775 MIDDLE EAST & AFRICA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 776 MIDDLE EAST & AFRICA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 777 MIDDLE EAST & AFRICA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 778 MIDDLE EAST & AFRICA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 779 MIDDLE EAST & AFRICA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 780 MIDDLE EAST & AFRICA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 781 MIDDLE EAST & AFRICA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 782 MIDDLE EAST & AFRICA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 783 MIDDLE EAST & AFRICA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 784 MIDDLE EAST & AFRICA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 785 MIDDLE EAST & AFRICA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 786 MIDDLE EAST & AFRICA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 787 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 788 MIDDLE EAST & AFRICA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
  • TABLE 789 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 790 MIDDLE EAST & AFRICA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 791 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 792 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 793 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 794 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 795 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 796 SAUDI ARABIA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 797 SAUDI ARABIA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 798 SAUDI ARABIA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 799 SAUDI ARABIA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 800 SAUDI ARABIA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 801 SAUDI ARABIA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 802 SAUDI ARABIA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 803 SAUDI ARABIA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 804 SAUDI ARABIA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 805 SAUDI ARABIA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 806 SAUDI ARABIA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 807 SAUDI ARABIA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 808 SAUDI ARABIA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 809 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 810 SAUDI ARABIA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
  • TABLE 811 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 812 SAUDI ARABIA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 813 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 814 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 815 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 816 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 817 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 818 SOUTH AFRICA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 819 SOUTH AFRICA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 820 SOUTH AFRICA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 821 SOUTH AFRICA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 822 SOUTH AFRICA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 823 SOUTH AFRICA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 824 SOUTH AFRICA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 825 SOUTH AFRICA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 826 SOUTH AFRICA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 827 SOUTH AFRICA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 828 SOUTH AFRICA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 829 SOUTH AFRICA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 830 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 831 SOUTH AFRICA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
  • TABLE 832 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 833 SOUTH AFRICA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 834 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 835 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 836 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 837 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 838 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 839 UAE PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 840 UAE ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 841 UAE INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 842 UAE INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 843 UAE GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 844 UAE INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 845 UAE INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 846 UAE ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 847 UAE CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 848 UAE IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 849 UAE SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 850 UAE MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 851 UAE FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 852 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 853 UAE BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
  • TABLE 854 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 855 UAE PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 856 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 857 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 858 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 859 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 860 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 861 ISRAEL PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 862 ISRAEL ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 863 ISRAEL INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 864 ISRAEL INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 865 ISRAEL GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 866 ISRAEL INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 867 ISRAEL INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 868 ISRAEL ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 869 ISRAEL CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 870 ISRAEL IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 871 ISRAEL SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 872 ISRAEL MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 873 ISRAEL FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 874 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 875 ISRAEL BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
  • TABLE 876 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 877 ISRAEL PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 878 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 879 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 880 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 881 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 882 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 883 KUWAIT PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 884 KUWAIT ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 885 KUWAIT INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 886 KUWAIT INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 887 KUWAIT GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 888 KUWAIT INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 889 KUWAIT INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 890 KUWAIT ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 891 KUWAIT CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 892 KUWAIT IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 893 KUWAIT SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 894 KUWAIT MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 895 KUWAIT FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 896 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 897 KUWAIT BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
  • TABLE 898 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 899 KUWAIT PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 900 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 901 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 902 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 903 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 904 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 905 EGYPT PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 906 EGYPT ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 907 EGYPT INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 908 EGYPT INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 909 EGYPT GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 910 EGYPT INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 911 EGYPT INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 912 EGYPT ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 913 EGYPT CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 914 EGYPT IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 915 EGYPT SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 916 EGYPT MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 917 EGYPT FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 918 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 919 EGYPT BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
  • TABLE 920 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 921 EGYPT PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 922 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 923 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 924 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 925 REST OF MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 926 SOUTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
  • TABLE 927 SOUTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 928 SOUTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 929 SOUTH AMERICA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 930 SOUTH AMERICA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 931 SOUTH AMERICA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 932 SOUTH AMERICA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 933 SOUTH AMERICA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 934 SOUTH AMERICA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 935 SOUTH AMERICA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 936 SOUTH AMERICA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 937 SOUTH AMERICA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 938 SOUTH AMERICA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 939 SOUTH AMERICA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 940 SOUTH AMERICA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 941 SOUTH AMERICA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 942 SOUTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 943 SOUTH AMERICA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)
  • TABLE 944 SOUTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 945 SOUTH AMERICA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 946 SOUTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 947 SOUTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 948 SOUTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 949 BRAZIL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 950 BRAZIL MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 951 BRAZIL PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 952 BRAZIL ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 953 BRAZIL INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 954 BRAZIL INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 955 BRAZIL GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 956 BRAZIL INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 957 BRAZIL INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 958 BRAZIL ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 959 BRAZIL CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 960 BRAZIL IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 961 BRAZIL SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 962 BRAZIL MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 963 BRAZIL FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 964 BRAZIL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 965 BRAZIL BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)
  • TABLE 966 BRAZIL MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 967 BRAZIL PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 968 BRAZIL MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 969 BRAZIL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 970 BRAZIL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 971 ARGENTINA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 972 ARGENTINA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 973 ARGENTINA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 974 ARGENTINA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 975 ARGENTINA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 976 ARGENTINA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 977 ARGENTINA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 978 ARGENTINA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 979 ARGENTINA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 980 ARGENTINA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 981 ARGENTINA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 982 ARGENTINA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 983 ARGENTINA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 984 ARGENTINA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 985 ARGENTINA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 986 ARGENTINA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 987 ARGENTINA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)
  • TABLE 988 ARGENTINA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 989 ARGENTINA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 990 ARGENTINA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 991 ARGENTINA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 992 ARGENTINA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 993 PERU MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
  • TABLE 994 PERU MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 995 PERU PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 996 PERU ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 997 PERU INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 998 PERU INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 999 PERU GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 1000 PERU INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 1001 PERU INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 1002 PERU ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 1003 PERU CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 1004 PERU IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 1005 PERU SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 1006 PERU MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 1007 PERU FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
  • TABLE 1008 PERU MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 1009 PERU BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)
  • TABLE 1010 PERU MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 1011 PERU PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 1012 PERU MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 1013 PERU MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 1014 PERU RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 1015 REST OF SOUTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: SEGMENTATION 74
  • FIGURE 2 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: DATA TRIANGULATION 77
  • FIGURE 3 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: DROC ANALYSIS 78
  • FIGURE 4 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 79
  • FIGURE 5 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 79
  • FIGURE 6 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 80
  • FIGURE 7 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: DBMR MARKET POSITION GRID 82
  • FIGURE 8 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: VENDOR SHARE ANALYSIS 83
  • FIGURE 9 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: SEGMENTATION 87
  • FIGURE 10 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2020 TO 2027 88
  • FIGURE 11 INCREASING PREVALENCE OF MULTIPLE SCLEROSIS AND RISING GOVERNMENT INITIATIVES ARE EXPECTED TO DRIVE THE GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 89
  • FIGURE 12 RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET IN 2020 & 2027 89
  • FIGURE 13 ASIA-PACIFIC IS THE FASTEST GROWING REGION FOR MULTIPLE SCLEROSIS TREATMENT MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2020 TO 2027 90
  • FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET 95
  • FIGURE 15 MULTIPLE SCLEROSIS PREVALENCE 96
  • FIGURE 16 MULTIPLE SCLEROSIS PREVALENCE BY GENDER 97
  • FIGURE 17 PIPELINE BY DEVELOPMENT PHASE, 2019 VERSUS 2018 98
  • FIGURE 18 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISEASE TYPE, 2019 108
  • FIGURE 19 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISEASE TYPE, 2019-2027 (USD MILLION) 109
  • FIGURE 20 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISEASE TYPE, CAGR (2020-2027) 109
  • FIGURE 21 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISEASE TYPE, LIFELINE CURVE 110
  • FIGURE 22 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: BY TREATMENT, 2019 114
  • FIGURE 23 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: BY TREATMENT, 2019-2027 (USD MILLION) 115
  • FIGURE 24 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: BY TREATMENT, CAGR (2020-2027) 115
  • FIGURE 25 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE 116
  • FIGURE 26 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: BY DRUG TYPE, 2019 130
  • FIGURE 27 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2019-2027 (USD MILLION) 131
  • FIGURE 28 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: BY DRUG TYPE, CAGR (2020-2027) 131
  • FIGURE 29 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE 132
  • FIGURE 30 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019 136
  • FIGURE 31 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION) 137
  • FIGURE 32 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027) 137
  • FIGURE 33 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 138
  • FIGURE 34 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: BY END USER, 2019 142
  • FIGURE 35 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2019-2027 (USD MILLION) 143
  • FIGURE 36 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: BY END USER, CAGR (2020-2027) 143
  • FIGURE 37 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: BY END USER, LIFELINE CURVE 144
  • FIGURE 38 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019 148
  • FIGURE 39 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION) 149
  • FIGURE 40 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027) 149
  • FIGURE 41 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 150
  • FIGURE 42 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: SNAPSHOT (2019) 155
  • FIGURE 43 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: BY REGION (2019) 156
  • FIGURE 44 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: BY REGION (2020 & 2027) 156
  • FIGURE 45 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: BY REGION (2019 & 2027) 157
  • FIGURE 46 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: BY TYPE (2020-2027) 157
  • FIGURE 47 NORTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET: SNAPSHOT (2019) 159
  • FIGURE 48 NORTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2019) 160
  • FIGURE 49 NORTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2020 & 2027) 160
  • FIGURE 50 NORTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2019 & 2027) 161
  • FIGURE 51 NORTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY TYPE (2020-2027) 161
  • FIGURE 52 ASIA-PACIFIC MULTIPLE SCLEROSIS TREATMENT MARKET: SNAPSHOT (2019) 190
  • FIGURE 53 ASIA-PACIFICMULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2019) 191
  • FIGURE 54 ASIA-PACIFICMULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2020 & 2027) 191
  • FIGURE 55 ASIA-PACIFICMULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2019 & 2027) 192
  • FIGURE 56 ASIA-PACIFICMULTIPLE SCLEROSIS TREATMENT MARKET: BY DISEASE TYPE (2020-2027) 192
  • FIGURE 57 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET: SNAPSHOT (2019) 279
  • FIGURE 58 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2019) 280
  • FIGURE 59 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2020 & 2027) 280
  • FIGURE 60 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2019 & 2027) 281
  • FIGURE 61 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISEASE TYPE (2020-2027) 281
  • FIGURE 62 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: SNAPSHOT (2019) 403
  • FIGURE 63 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2019) 404
  • FIGURE 64 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2020 & 2027) 404
  • FIGURE 65 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2019 & 2027) 405
  • FIGURE 66 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY TYPE (2020-2027) 405
  • FIGURE 67 SOUTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET: SNAPSHOT (2019) 457
  • FIGURE 68 SOUTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2019) 458
  • FIGURE 69 SOUTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2020 & 2027) 458
  • FIGURE 70 SOUTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2019 & 2027) 459
  • FIGURE 71 SOUTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISEASE TYPE (2020-2027) 459
  • FIGURE 72 GLOBAL MULTIPLE SCLEROSIS TREATMENT MARKET: COMPANY SHARE 2019 (%) 489
  • FIGURE 73 NORTH AMERICA MULTIPLE SCLEROSIS TREATMENT MARKET: COMPANY SHARE 2019 (%) 490
  • FIGURE 74 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET: COMPANY SHARE 2019 (%) 491
  • FIGURE 75 ASIA-PACIFIC MULTIPLE SCLEROSIS TREATMENT MARKETMARKET: COMPANY SHARE 2019 (%) 492